i3 Analytics' ClinicalTrials Navigator Sees A New Dawn for Multiple Sclerosis …PR Web (press release)In addition to the aforementioned drugs that are pending FDA approval, there are several promising therapies in the later stages of clinical deve…
Treatment of Adult Acute Lymphoblastic Leukemia (ALL) With a Focus on …Cancer Network[17] The prognostic role of CD20 expression in ALL is controversial; nonetheless, targeted therapies directed against this marker have been developed. Recent data fr…
Search local inventory, coupons and moreThe Herald | HeraldOnline.comPatient profiles for the seven DMAs in late clinical development (teriflunomide, BG-12, alemtuzumab, PEG-Avonex, daclizumab, laquinimod, ocrelizumab) are also characterized. About Bio…
New BioTrends Chart Audit Measures the Impact of Recent Multiple Sclerosis …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (teriflunomide, BG-12, alemtuzumab, PEG-Avonex, daclizumab, laquinimod, ocrelizuma…
Proactive Investors USA & CanadaCTI launches Pixuvri in EU to treat adult patients with refractory aggressive …pharmabiz.comThe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoin…
Proactive Investors USA & CanadaCell Therapeutics Announces European Launch Of Pixuvri® For Treatment Of …Sacramento BeeThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI…
Proactive Investors USA & CanadaCell Therapeutics shares surge on commercial launch of lymphoma drug in …Proactive Investors USA & CanadaThe company said it is also currently accruing patients into a phase 3 trial comparing pixantrone and rituximab w…
Elan unlikely target for Biogen given latter's focus on MS drug BG-12Financial TimesIn addition, the company is advancing daclizumab, an IL-2R antibody, in what will be the largest MS study ever conducted. Data is expected in 2014. On 13 August 201…
Cell Therapeutics Announces European Launch of Pixuvri(R) for Treatment of …PR Newswire UK (press release)The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing …
-First and only approved therapy for this patient population PR NewswireEquities.comThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled ph…